<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the effects of L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> compared with placebo or control on morbidity and mortality in the setting of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A systematic review and meta-analysis of 13 controlled trials (N=3629) was conducted to determine the effects of L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> vs placebo or control on mortality, <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> (VAs), <z:mp ids='MP_0006112'>angina</z:mp>, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and reinfarction </plain></SENT>
<SENT sid="2" pm="."><plain>These trials were identified via searches of the Ovid MEDLINE, PubMed, and Excerpta Medica (Embase) databases between May 1, 2012, and August 31,Â 2012 </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Compared with placebo or control, L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> was associated with a significant 27% reduction in <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality (odds ratio, 0.73; 95% CI, 0.54-0.99; P=.05; risk ratio [RR], 0.78; 95% CI, 0.60-1.00; P=.05), a highly significant 65% reduction in VAs (RR, 0.35; 95% CI, 0.21-0.58; P&lt;.0001), and a significant 40% reduction in the development of <z:mp ids='MP_0006112'>angina</z:mp> (RR, 0.60; 95% CI, 0.50-0.72; P&lt;.00001), with no reduction in the development of <z:hpo ids='HP_0001635'>heart failure</z:hpo> (RR, 0.85; 95% CI, 0.67-1.09; P=.21) or <z:e sem="disease" ids="C0948369" disease_type="Disease or Syndrome" abbrv="">myocardial reinfarction</z:e> (RR, 0.78; 95% CI, 0.41-1.48; P=.45) </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: Compared with placebo or control, L-<z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> is associated with a 27% reduction in <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, a 65% reduction in VAs, and a 40% reduction in anginal symptoms in patients experiencing an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Further study with large randomized controlled trials of this inexpensive and safe therapy in the modern era is warranted </plain></SENT>
</text></document>